160 related articles for article (PubMed ID: 9038218)
1. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins.
Chen G; Durán GE; Steger KA; Lacayo NJ; Jaffrézou JP; Dumontet C; Sikic BI
J Biol Chem; 1997 Feb; 272(9):5974-82. PubMed ID: 9038218
[TBL] [Abstract][Full Text] [Related]
2. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
3. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335).
Chen KG; Lacayo NJ; Durán GE; Cohen D; Sikic BI
Mol Pharmacol; 2000 Apr; 57(4):769-77. PubMed ID: 10727524
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection.
Chen KG; Jaffrézou JP; Fleming WH; Durán GE; Sikic BI
Cancer Res; 1994 Sep; 54(18):4980-7. PubMed ID: 7915196
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance.
Hofmann J; Gekeler V; Ise W; Noller A; Mitterdorfer J; Hofer S; Utz I; Gotwald M; Boer R; Glossmann H
Biochem Pharmacol; 1995 Mar; 49(5):603-9. PubMed ID: 7887974
[TBL] [Abstract][Full Text] [Related]
6. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
Chen GK; Durán GE; Mangili A; Beketic-Oreskovic L; Sikic BI
Br J Cancer; 2000 Oct; 83(7):892-8. PubMed ID: 10970691
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
8. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
9. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
10. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):281-4. PubMed ID: 11031728
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Aouali N; El Btaouri H; Dumontet C; Eddabra L; Malagarie-Cazenave S; Madoulet C; Morjani H
Oncol Rep; 2011 Apr; 25(4):1161-7. PubMed ID: 21318225
[TBL] [Abstract][Full Text] [Related]
14. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
15. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma.
Chen KG; Lacayo NJ; Durán GE; Wang Y; Bangs CD; Rea S; Kovacs M; Cherry AM; Brown JM; Sikic BI
Genes Chromosomes Cancer; 2002 Aug; 34(4):372-83. PubMed ID: 12112526
[TBL] [Abstract][Full Text] [Related]
16. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation.
Hu YP; Chapey C; Robert J
Cancer Lett; 1996 Dec; 109(1-2):203-9. PubMed ID: 9020922
[TBL] [Abstract][Full Text] [Related]
17. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1.
Zhang X; Collins KI; Greenberger LM
J Biol Chem; 1995 Mar; 270(10):5441-8. PubMed ID: 7890659
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
[TBL] [Abstract][Full Text] [Related]
19. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine.
Gosland MP; Gillespie MN; Tsuboi CP; Tofiq S; Olson JW; Crooks PA; Aziz SM
Cancer Chemother Pharmacol; 1996; 37(6):593-600. PubMed ID: 8612315
[TBL] [Abstract][Full Text] [Related]
20. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
